- •Cognitive profile and physician-based and patients-reported outcomes could have a considerable impact on the disease management and on treatment decision making.
- •According to the Control Preference Scale, more than 50% of patients who needed to change therapy chose a “collaborative” role in making treatment decision.
- •Cognitive profile with SDMT seems to influence patients’ preference on treatment decision.
Clinicians are increasingly recognizing the importance of shared decision-making in complex treatment choices, highlighting the importance of the patient's rationale and motivation for switching therapies. This study aimed to evaluate the association between different modalities of changing multiple sclerosis (MS) treatments, cognitive profile and attitude and preferences of patients concerning treatment choice.
This multicenter cross-sectional study was conducted at 28 Italian MS centers in the period between June 2016 and June 2017. We screened all MS patients treated with any DMT, with a treatment compliance of at least 80% of therapy administered during the 3 last months who needed to modify MS therapy because of efficacy, safety or other reasons during a follow-up visit. At the time of switching the symbol digit modalities test (SDMT) and the Control Preference Scale (CPS) were evaluated. According to the CPS, patients were classified as “active” (i.e. who prefer making the medical decision themselves), “collaborative” (i.e. who prefer decisions be made jointly with the physician), or “passive” (i.e. who prefer the physician make the decision).
Out of 13,657 patients recorded in the log, 409 (3%) changed therapy. Of these, 336 (2.5%) patients, 69.6% were female and with mean age 40.6 ± 10.5 years, were enrolled. According to the CPS score evaluation, a significant high percentage of patients (51.1%) were considered collaborative, 74 patients (22.5%) were passive, and 60 (18.2%) patients were active. Stratifying according to CPS results, we found a higher SDMT score among collaborative patients compared to active and passive ones (45.8 ± 12.3 versus 41.0 ± 13.2 versus 41.7 ± 12.8, p < 0.05).
In this study, the CPS evaluation showed that more than 50% of patients who needed to change therapy chose a “collaborative” role in making treatment decision. Cognitive profile with SDMT seems to correlate with patients’ preference on treatment decision, showing better scores in collaborative patients.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Decision making process in multiple sclerosis: an argentine pilot study.Mult. Scler. Relat. Disord. 2022; 61103751
- The rao's brief repeatable battery and stroop test: normative values with age, education and gender corrections in an Italian population.Mult. Scler. 2006; 12: 787-793
- Capacity to make medical treatment decisions in multiple sclerosis: a potentially remediable deficit.J. Clin. Exp. Neuropsychol. 2010; 32: 1050-1061
- Shared decision making and autonomy among US participants with multiple sclerosis in the NARCOMS registry.Int. J. MS Care. 2017; 19: 303-312
- Multiple sclerosis.Lancet. 2008; 372: 1502-1517
- Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.Medscape J. Med. 2008; 10: 225
- Switching therapies in multiple sclerosis.CNS Drugs. 2013; 27: 239-247
- Disability may influence patient willingness to participate in decision making on first-line therapy in multiple sclerosis.Funct. Neurol. 2016; 31: 21-23
- The control preferences scale.Can. J. Nurs. Res. 1997; 29: 21-43
- Shared decision making: developing the OPTION scale for measuring patient involvement.Qual. Saf. Health Care. 2003; 12: 93-99
- Treatment optimization in multiple sclerosis.Can. J. Neurol. Sci. 2004; 31: 157-168
- Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.Mult. Scler. 2009; 15: 50-58
- Treatment strategies for multiple sclerosis: when to start, when to change, when to stop?.World J. Clin. Cases. 2015; 3: 545-555
- Medical decision-making capacity and its cognitive predictors in progressive MS: preliminary evidence.J. Neurol. Sci. 2017; 380: 38-43
- Participation in medical decision-making: attitudes of Italians with multiple sclerosis.J. Neurol. Sci. 2008; 275: 86-91
- Participation preferences of patients with acute and chronic conditions.Health Expect. 2007; 10: 358-363
- Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis.Mult. Scler. 2004; 10: 643-650
- Do Alzheimer's disease patients want to participate in a treatment decision, and would their caregivers let them?.Gerontologist. 2005; 45: 381-388
- Distinct cognitive impairments in different disease courses of multiple sclerosis-A systematic review and meta-analysis.Neurosci. Biobehav. Rev. 2017; 83: 568-578
- Not all patients want to participate in decision making. A national study of public preferences.J. Gen. Intern. Med. 2005; 20: 531-535
- Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis.Neurology. 1996; 46: 907-911
- Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.Expert. Rev. Neurother. 2014; 14: 1029-1042
- Clinical factors that influence patients' desire for participation in decisions about illness.Arch. Intern. Med. 2000; 160: 2991-2996
- Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia.Mov. Disord. 2008; 23: 1867-1874
- Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis.Ther. Adv. Neurol. Disord. 2019; 121756286419892077
- Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome.PLoS One. 2012; 7: e38661
- Switching or discontinuing disease-modifying therapies for multiple sclerosis.Continuum. 2016; 22 (Minneap Minn): 851-863
- Decision-making in multiple sclerosis patients: a systematic review.Mult. Scler. Int. 2018; 20187835952
- The symbol digit modalities test - oral version: Italian normative data.Funct. Neurol. 2006; 21: 93-96
- Medical decision-making capacity in patients with mild cognitive impairment.Neurology. 2007; 69: 1528-1535
- Cognitive models of medical decision-making capacity in patients with mild cognitive impairment.J. Int. Neuropsychol. Soc. 2008; 14: 297-308
- Cognitive impairment in multiple sclerosis.Mult. Scler. 2009; 15: 2-8
- Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study).Mult. Scler. Relat. Disord. 2020; 42102124
- Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments.PLoS One. 2013; 8: e60721
- Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response.Eur. J. Neurol. 2012; 19: 899-904
- Reasons for discontinuation of subcutaneous interferon beta-1a three times a week among patients with multiple sclerosis: a real-world cohort study.BMC Neurol. 2017; 17: 57
- The multiple sclerosis care unit.Mult. Scler. 2019; 25: 627-636
- Role preferences of people with multiple sclerosis: image-revised, computerized self-administered version of the control preference scale.PLoS One. 2013; 8: e66127
- Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.Mult. Scler. 2014; 20: 830-836
- Information needs and preferences for participation in treatment decisions among Swedish breast cancer patients.Acta Oncol. 2000; 39: 467-476
- Initiating disease-modifying treatments in multiple sclerosis: measuring the decision process using decisional conflict and decisional regret scales.Mult. Scler. J. Exp. Transl. Clin. 2019; 52055217319833006
Published online: December 18, 2022
Accepted: December 18, 2022
Received in revised form: December 14, 2022
Received: September 27, 2022
© 2022 Elsevier B.V. All rights reserved.